Adynxx meets in pain relief Phase II

Adynxx Inc. (San Fransisco, Calif.) said AYX1 significantly reduced pain in a placebo-controlled Phase II trial to reduce acute and chronic pain. AYX1, a small synthetic dsDNA inhibitor of early growth response 1 ( EGR1), is a first-in-class treatment for the indication.

Adynxx said that in the 120-patient study, AYX1 significantly reduced pain with walking from day 7 to day 28 after knee replacement surgery, the study's primary endpoint. Pain reduction was maintained for the 42-day study period. Pain at rest from day 7 to day 28, the study's secondary endpoint, also was significantly improved. ...